Infectious Complications Associated with Immunomodulating Biologic Agents

Hematology/Oncology Clinics of North America

Volumn 25, Issue 1, 2011, Pages 117-138

  Koo, Sophia ^a,b,c   Marty, Francisco M ^a,b,c   Baden, Lindsey R ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Biologic therapies; Infectious complications; Monoclonal antibodies

Indexed keywords

ABATACEPT; ACICLOVIR; ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; BELATACEPT; CERTOLIZUMAB PEGOL; CYCLOPHOSPHAMIDE; DACLIZUMAB; DOXORUBICIN; EFALIZUMAB; ETANERCEPT; GAMMA INTERFERON; GEMTUZUMAB OZOGAMICIN; GOLIMUMAB; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 2; METHOTREXATE; NATALIZUMAB; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; RITUXIMAB; SULFAMETHOXAZOLE; TRIMETHOPRIM; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VINCRISTINE SULFATE;

ANKYLOSING SPONDYLITIS; BABESIA MICROTI; CHRONIC LYMPHATIC LEUKEMIA; CROHN DISEASE; CYTOMEGALOVIRUS; DISEASE SURVEILLANCE; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MYCOSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; TUBERCULOSIS; ULCERATIVE COLITIS; VARICELLA ZOSTER VIRUS;

EID: 78651103644     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.11.009     Document Type: Review

References (163)

1. Shortt J., Spencer A. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 2006, 38:433.
2. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825.
3. Byrd J.C., Rai K., Peterson B.L., et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005, 105:49.
4. Rafailidis P.I., Kakisi O.K., Vardakas K., et al. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 2007, 109:2182.
5. Aksoy S., Dizdar O., Hayran M., et al. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leuk Lymphoma 2009, 50:357.
6. Vidal L., Gafter-Gvili A., Leibovici L., et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009, 101:248.
7. Spina M., Jaeger U., Sparano J.A., et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 2005, 105:1891.
8. Kaplan L.D., Lee J.Y., Ambinder R.F., et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005, 106:1538.
9. Boue F., Gabarre J., Gisselbrecht C., et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 2006, 24:4123.
10. Dervite I., Hober D., Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001, 344:68.
11. Tsutsumi Y., Tanaka J., Kawamura T., et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004, 83:58.
12. Yeo W., Chan T.C., Leung N.W., et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009, 27:605.
13. Garcia-Rodriguez M.J., Canales M.A., Hernandez-Maraver D., et al. Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment?. Am J Hematol 2008, 83:673.
14. Hamaki T., Kami M., Kusumi E., et al. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol 2001, 68:292.
15. Yeo W., Johnson P.J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006, 43:209.
16. Carson K.R., Focosi D., Major E.O., et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009, 10:816.
17. Carson K.R., Evens A.M., Richey E.A., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009, 113:4834.
18. Krause P.J., Gewurz B.E., Hill D., et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis 2008, 46:370.
19. Kumar D., Gourishankar S., Mueller T., et al. Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient. Transpl Infect Dis 2009, 11:167.
20. Teichmann L.L., Woenckhaus M., Vogel C., et al. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:1256.
21. Venhuizen A.C., Hustinx W.N., van Houte A.J., et al. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma. Eur J Haematol 2008, 80:275.
22. Lund F.E., Hollifield M., Schuer K., et al. B cells are required for generation of protective effector and memory CD4 cells in response to pneumocystis lung infection. J Immunol 2006, 176:6147.
23. Marcotte H., Levesque D., Delanay K., et al. Pneumocystis carinii infection in transgenic B cell-deficient mice. J Infect Dis 1996, 173:1034.
24. Winthrop K.L., Yamashita S., Beekmann S.E., et al. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 2008, 46:1738.
25. Chen Y.C., Jou R., Huang W.L., et al. Bacteremia caused by Mycobacterium wolinskyi. Emerg Infect Dis 2008, 14:1818.
26. Lutt J.R., Pisculli M.L., Weinblatt M.E., et al. Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis. J Rheumatol 2008, 35:1683.
27. Maglione P.J., Xu J., Chan J. B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis. J Immunol 2007, 178:7222.
28. Ulrichs T., Kosmiadi G.A., Trusov V., et al. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J Pathol 2004, 204:217.
29. Archimbaud C., Bailly J.L., Chambon M., et al. Molecular evidence of persistent echovirus 13 meningoencephalitis in a patient with relapsed lymphoma after an outbreak of meningitis in 2000. J Clin Microbiol 2003, 41:4605.
30. Padate B.P., Keidan J. Enteroviral meningoencephalitis in a patient with non-Hodgkin's lymphoma treated previously with rituximab. Clin Lab Haematol 2006, 28:69.
31. Quartier P., Tournilhac O., Archimbaud C., et al. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin Infect Dis 2003, 36:e47.
32. Goldberg S.L., Pecora A.L., Alter R.S., et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002, 99:1486.
33. Lee M.Y., Chiou T.J., Hsiao L.T., et al. Rituximab therapy increased post-transplant cytomegalovirus complications in non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation. Ann Hematol 2008, 87:285.
34. Suzan F., Ammor M., Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001, 345:1000.
35. Bermudez A., Marco F., Conde E., et al. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 2000, 85:894.
36. McIlwaine L.M., Fitzsimons E.J., Soutar R.L. Inappropriate antidiuretic hormone secretion, abdominal pain and disseminated varicella-zoster virus infection: an unusual and fatal triad in a patient 13 months post rituximab and autologous stem cell transplantation. Clin Lab Haematol 2001, 23:253.
37. Crowley B., Woodcock B. Red cell aplasia due to parvovirus b19 in a patient treated with alemtuzumab. Br J Haematol 2002, 119:279.
38. Isobe Y., Sugimoto K., Shiraki Y., et al. Successful high-titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab-combined chemotherapy. Am J Hematol 2004, 77:370.
39. Sharma V.R., Fleming D.R., Slone S.P. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000, 96:1184.
40. Huang C., Slater B., Rudd R., et al. First isolation of West Nile virus from a patient with encephalitis in the United States. Emerg Infect Dis 2002, 8:1367.
41. Levi M.E., Quan D., Ho J.T., et al. Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients. Clin Transplant 2009, [Epub ahead of print].
42. Mawhorter S.D., Sierk A., Staugaitis S.M., et al. Fatal West Nile Virus infection after rituximab/fludarabine-induced remission for non-Hodgkin's lymphoma. Clin Lymphoma Myeloma 2005, 6:248.
43. Flohr T.R., Sifri C.D., Brayman K.L., et al. Nocardiosis in a renal transplant recipient following rituximab preconditioning. Ups J Med Sci 2009, 114:62.
44. Kundranda M.N., Spiro T.P., Muslimani A., et al. Cerebral nocardiosis in a patient with NHL treated with rituximab. Am J Hematol 2007, 82:1033.
45. Scallon B., Cai A., Solowski N., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002, 301:418.
46. Algood H.M., Lin P.L., Flynn J.L. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 2005, 41(Suppl 3):S189.
47. Harris J., Hope J.C., Keane J. Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis. J Infect Dis 2008, 198:1842.
48. Roach D.R., Bean A.G., Demangel C., et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002, 168:4620.
49. Dixon W.G., Symmons D.P., Lunt M., et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007, 56:2896.
50. Listing J., Strangfeld A., Kary S., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005, 52:3403.
51. Askling J., Fored C.M., Brandt L., et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007, 66:1339.
52. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275.
53. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098.
54. Wallis R.S., Broder M., Wong J., et al. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004, 39:1254.
55. Wallis R.S., Broder M.S., Wong J.Y., et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38:1261.
56. Brassard P., Kezouh A., Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006, 43:717.
57. Wallis R.S. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum 2008, 58:947.
58. Arend S.M., Leyten E.M., Franken W.P., et al. A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis 2007, 45:1470.
59. Wallis R.S., van Vuuren C., Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 2009, 48:1429.
60. Oberstein E.M., Kromo O., Tozman E.C. Type I reaction of Hansen's disease with exposure to adalimumab: a case report. Arthritis Rheum 2008, 59:1040.
61. Scollard D.M., Joyce M.P., Gillis T.P. Development of leprosy and type 1 leprosy reactions after treatment with infliximab: a report of 2 cases. Clin Infect Dis 2006, 43:e19.
62. Vilela Lopes R., Barros Ohashi C., Helena Cavaleiro L., et al. Development of leprosy in a patient with ankylosing spondylitis during the infliximab treatment: reactivation of a latent infection?. Clin Rheumatol 2009, 28:615.
63. Marie I., Heliot P., Roussel F., et al. Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab. Rheumatology (Oxford) 2005, 44:1201.
64. Martin-Aspas A., Guerrero-Sanchez F., Garcia-Martos P., et al. Bilateral pneumonia by Mycobacterium aurum in a patient receiving infliximab therapy. J Infect 2008, 57:167.
65. Larsen M.V., Sorensen I.J., Thomsen V.O., et al. Re-activation of bovine tuberculosis in a patient treated with infliximab. Eur Respir J 2008, 32:229.
66. van Ingen J., Boeree M., Janssen M., et al. Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. Nat Clin Pract Rheumatol 2007, 3:414.
67. Lee J.H., Slifman N.R., Gershon S.K., et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002, 46:2565.
68. Asrani N.S. Disseminated histoplasmosis associated with the treatment of rheumatoid arthritis with anticytokine therapy. Ann Intern Med 2008, 149:594.
69. Wood K.L., Hage C.A., Knox K.S., et al. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med 2003, 167:1279.
70. Tsiodras S., Samonis G., Boumpas D.T., et al. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008, 83:181.
71. Bergstrom L., Yocum D.E., Ampel N.M., et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 2004, 50:1959.
72. Pena-Sagredo J.L., Hernandez M.V., Fernandez-Llanio N., et al. Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience. Clin Exp Rheumatol 2008, 26:854.
73. Slifman N.R., Gershon S.K., Lee J.H., et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003, 48:319.
74. Li Gobbi F., Benucci M., Del Rosso A. Pneumonitis caused by Legionella pneumoniae in a patient with rheumatoid arthritis treated with anti-TNF-alpha therapy (infliximab). J Clin Rheumatol 2005, 11:119.
75. Wondergem M.J., Voskuyl A.E., van Agtmael M.A. A case of legionellosis during treatment with a TNFalpha antagonist. Scand J Infect Dis 2004, 36:310.
76. Fu A., Bertouch J.V., McNeil H.P. Disseminated Salmonella typhimurium infection secondary to infliximab treatment. Arthritis Rheum 2004, 50:3049.
77. Netea M.G., Radstake T., Joosten L.A., et al. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and toll-like receptor 4 expression. Arthritis Rheum 2003, 48:1853.
78. Bagalas V., Kioumis I., Argyropoulou P., et al. Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept. Clin Rheumatol 2007, 26:1344.
79. Fabre S., Gibert C., Lechiche C., et al. Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab. Clin Exp Rheumatol 2005, 23:891.
80. Mueller M.C., Fleischmann E., Grunke M., et al. Relapsing cutaneous leishmaniasis in a patient with ankylosing spondylitis treated with infliximab. Am J Trop Med Hyg 2009, 81:52.
81. Geraghty E.M., Ristow B., Gordon S.M., et al. Overwhelming parasitemia with Plasmodium falciparum infection in a patient receiving infliximab therapy for rheumatoid arthritis. Clin Infect Dis 2007, 44:e82.
82. Coyle C.M., Weiss L.M., Rhodes L.V., et al. Fatal myositis due to the microsporidian Brachiola algerae, a mosquito pathogen. N Engl J Med 2004, 351:42.
83. Roilides E., Dimitriadou-Georgiadou A., Sein T., et al. Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus. Infect Immun 1998, 66:5999.
84. Gottlieb G.S., Lesser C.F., Holmes K.K., et al. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists. Clin Infect Dis 2003, 37:838.
85. Lowther A.L., Somani A.K., Camouse M., et al. Invasive Trichophyton rubrum infection occurring with infliximab and long-term prednisone treatment. J Cutan Med Surg 2007, 11:84.
86. Harigai M., Koike R., Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 2007, 357:1874.
87. Kaur N., Mahl T.C. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007, 52:1481.
88. Takeuchi T., Tatsuki Y., Nogami Y., et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67:189.
89. Garcia-Vidal C., Rodriguez-Fernandez S., Teijon S., et al. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009, 28:331.
90. Strangfeld A., Listing J., Herzer P., et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009, 301:737.
91. Smitten A.L., Choi H.K., Hochberg M.C., et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007, 57:1431.
92. Bradford R.D., Pettit A.C., Wright P.W., et al. Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors. Clin Infect Dis 2009, 49:924.
93. Esteve M., Saro C., Gonzalez-Huix F., et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004, 53:1363.
94. Michel M., Duvoux C., Hezode C., et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 2003, 30:1624.
95. Zingarelli S., Frassi M., Bazzani C., et al. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol 2009, 36:1188.
96. Roux C.H., Brocq O., Breuil V., et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 2006, 45:1294.
97. Couriel D., Saliba R., Hicks K., et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004, 104:649.
98. Marty F.M., Lee S.J., Fahey M.M., et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003, 102:2768.
99. Keystone E., Heijde D., Mason D., et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008, 58:3319.
100. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007, 357:239.
101. Smolen J., Landewe R.B., Mease P., et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009, 68:797.
102. Keystone E.C., Genovese M.C., Klareskog L., et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009, 68:789.
103. Wenzel S.E., Barnes P.J., Bleecker E.R., et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009, 179:549.
104. Furst D.E., Keystone E.C., Kirkham B., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2008, 67(Suppl 3). iii2.
105. Salliot C., Dougados M., Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009, 68:25.
106. Le Loet X., Nordstrom D., Rodriguez M., et al. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial. J Rheumatol 2008, 35:1538.
107. Lequerre T., Quartier P., Rosellini D., et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset still disease: preliminary experience in France. Ann Rheum Dis 2008, 67:302.
108. Hoffman H.M., Throne M.L., Amar N.J., et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008, 58:2443.
109. Morris E.C., Rebello P., Thomson K.J., et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 2003, 102:404.
110. Rai K.R., Freter C.E., Mercier R.J., et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002, 20:3891.
111. Ferrajoli A., O'Brien S.M., Cortes J.E., et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003, 98:773.
112. Keating M.J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99:3554.
113. Martin S.I., Marty F.M., Fiumara K., et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006, 43:16.
114. Lundin J., Kimby E., Bjorkholm M., et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002, 100:768.
115. Hillmen P., Skotnicki A.B., Robak T., et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007, 25:5616.
116. Saadeh C.E., Srkalovic G. Mycobacterium avium complex infection after alemtuzumab therapy for chronic lymphocytic leukemia. Pharmacotherapy 2008, 28:281.
117. Abad S., Gyan E., Moachon L., et al. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration. Clin Infect Dis 2003, 37:e27.
118. Kamboj M., Louie E., Kiehn T., et al. Mycobacterium haemophilum infection after alemtuzumab treatment. Emerg Infect Dis 2008, 14:1821.
119. Dungarwalla M., Field-Smith A., Jameson C., et al. Cutaneous Mycobacterium chelonae infection in chronic lymphocytic leukaemia. Haematologica 2007, 92:e5.
120. Chae Y.S., Sohn S.K., Kim J.G., et al. Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors. Am J Hematol 2008, 83:649.
121. Chakrabarti S., Mackinnon S., Chopra R., et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002, 99:4357.
122. Ho A.Y., Pagliuca A., Kenyon M., et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004, 104:1616.
123. Perez-Simon J.A., Kottaridis P.D., Martino R., et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002, 100:3121.
124. Chakrabarti S., Avivi I., Mackinnon S., et al. Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. Br J Haematol 2002, 119:1125.
125. Vu T., Carrum G., Hutton G., et al. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2007, 39:705.
126. Landgren O., Gilbert E.S., Rizzo J.D., et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009, 113:4992.
127. Peleg A.Y., Husain S., Kwak E.J., et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007, 44:204.
128. Laurenti L., Piccioni P., Cattani P., et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica 2004, 89:1248.
129. O'Brien S., Ravandi F., Riehl T., et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 2008, 111:1816.
130. Hengster P., Pescovitz M.D., Hyatt D., et al. Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group. Transplantation 1999, 68:310.
131. Vincenti F., Kirkman R., Light S., et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998, 338:161.
132. Hershberger R.E., Starling R.C., Eisen H.J., et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005, 352:2705.
133. Iversen M., Burton C.M., Vand S., et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis 2007, 26:879.
134. Przepiorka D., Kernan N.A., Ippoliti C., et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000, 95:83.
135. Perales M.A., Ishill N., Lomazow W.A., et al. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant 2007, 40:481.
136. Keown P., Balshaw R., Khorasheh S., et al. Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation. BioDrugs 2003, 17:271.
137. Lawen J.G., Davies E.A., Mourad G., et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 2003, 75:37.
138. Sheashaa H.A., Bakr M.A., Ismail A.M., et al. Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study. Clin Exp Nephrol 2008, 12:376.
139. Mattei M.F., Redonnet M., Gandjbakhch I., et al. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. J Heart Lung Transplant 2007, 26:693.
140. Mehra M.R., Zucker M.J., Wagoner L., et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 2005, 24:1297.
141. Lupo L., Panzera P., Tandoi F., et al. Basiliximab versus steroids in double therapy immunosuppression in liver transplantation: a prospective randomized clinical trial. Transplantation 2008, 86:925.
142. Neuhaus P., Clavien P.A., Kittur D., et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002, 8:132.
143. Brennan D.C., Daller J.A., Lake K.D., et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006, 355:1967.
144. Kremer J.M., Genant H.K., Moreland L.W., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006, 144:865.
145. Weinblatt M., Combe B., Covucci A., et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006, 54:2807.
146. Weinblatt M., Schiff M., Goldman A., et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007, 66:228.
147. Genovese M.C., Becker J.C., Schiff M., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005, 353:1114.
148. Genovese M.C., Schiff M., Luggen M., et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008, 67:547.
149. Bigbee C.L., Gonchoroff D.G., Vratsanos G., et al. Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice. Arthritis Rheum 2007, 56:2557.
150. Vincenti F., Larsen C., Durrbach A., et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005, 353:770.
151. Goodin D.S., Cohen B.A., O'Connor P., et al. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 71:766.
152. Kleinschmidt-DeMasters B.K., Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005, 353:369.
153. Langer-Gould A., Atlas S.W., Green A.J., et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005, 353:375.
154. Van Assche G., Van Ranst M., Sciot R., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005, 353:362.
155. Yousry T.A., Major E.O., Ryschkewitsch C., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006, 354:924.
156. Balato A., Balato N., Patruno C., et al. Visceral leishmaniasis infection in a patient with psoriasis treated with efalizumab. Dermatology 2008, 217:360.
157. Tuxen A.J., Yong M.K., Street A.C., et al. Disseminated cryptococcal infection in a patient with severe psoriasis treated with efalizumab, methotrexate and ciclosporin. Br J Dermatol 2007, 157:1067.
158. Miquel F.J., Colomina J., Marii J.I., et al. Cytomegalovirus infection in a patient treated with efalizumab for psoriasis. Arch Dermatol 2009, 145:961.
159. Gottlieb A.B., Casale T.B., Frankel E., et al. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol 2003, 49:816.
160. Brimhall A.K., King L.N., Licciardone J.C., et al. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008, 159:274.
161. Al-Tawfiq J.A., Al-Khatti A.A. Disseminated systemic Nocardia farcinica infection complicating alefacept and infliximab therapy in a patient with severe psoriasis. Int J Infect Dis 2009, 14:e153.
162. Prasertsuntarasai T., Bello E.F. Mycobacterium avium complex olecranon bursitis in a patient treated with alefacept. Mayo Clin Proc 2005, 80:1532.
163. Sievers E.L., Larson R.A., Stadtmauer E.A., et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001, 19:3244.